spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Synpromics announces a research collaboration with GE Healthcare to extend the toolbox for production of biologics

Synpromics

It will see the development of a complex bar-coded library of synthetic promoters

Edinburgh, UK, 4th January 2017 – Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.

Synpromics will develop a complex bar-coded library of synthetic promoters, using its proprietary PromPT™ platform, for extensive screening in GE Healthcare’s Chinese Hamster Ovary (CHO)-based expression system. The resulting characterised promoter toolbox is anticipated to have broad applicability for increasing the yield of a range of biopharmaceuticals, including proteins difficult to manufacture. GE Healthcare is paying an upfront technology access fee and will have the rights to commercialise the improved platform.

Dr David Venables, CEO of Synpromics, commented, “We are delighted to be working with GE Healthcare, a world leading technology innovator to develop and commercialise our novel synthetic promoter platform. We believe our synthetic promoters will provide a much more efficient production system and we’re aiming to help GE Healthcare boost efficiency for its biopharma customers.”

“We are happy to be able to collaborate with Synpromics on developing enhanced tools for manufacturing biologics and thereby support our customers in their production efforts,” said Morgan Norris, GM, Upstream and Cell Culture for GE Healthcare’s Life Sciences business.

About Synpromics
Synpromics is a private company focused on commercialising its proprietary technology in the emerging field of synthetic biology by developing customised synthetic promoters. The company has partnership deals with a number of gene therapy companies including AGTC, Adverum and uniQure.

Synpromics technology gives biological researchers, developers and manufacturers unprecedented control of gene expression through the ability to create a comprehensive portfolio of man-made DNA sequences. This is a highly disruptive technology as most of the currently used promoters are natural viral or gene specific promoters. Synpromics’ products comprise patented synthetic promoters that are designed to regulate genes in a highly specific manner. For more information see www.synpromics.com

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE Healthcare (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions GE Healthcare helps medical professionals deliver great healthcare to their patients. www.gehealthcare.com

Media Contact
Deborah Cockerill
Sciad Communications Ltd
+44 (0)7930 317729
deborah@sciad.com

Corporate Contact
Dr David Venables, CEO
Synpromics Ltd
+44 (0)7825 323439
david.venables@synpromics.com
phone +44 (0) 131 651 9662
email info@synpromics.com
web www.synpromics.com
email Roslin Innovation Centre, Easter Bush Campus, Midlothian, EH25 9RG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioIVT Webinar Will Discuss How to Optimize Microbiome Research

BioIVT, a leading provider of research models and services for drug development, today announced that it is hosting a webinar entitled “The Microbiome: Understanding Why Collection and Processing Matters” at 11 a.m. ET on July 25.
More info >>


White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

Industry Events

Clinical Trial Supply Southeast 2018

2-3 October 2018, Cary, North Carolina

Clinical Trial Supply Southeast will return to Cary, North Carolina for fall 2018. Part of our global series of events, this show will attract the leading biotech and pharma companies from the Southeast region, the event will focus on how companies can adapt their supply chains to fit into the highly regulated world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement